Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

The Structure of CIMZIA

TNF-alpha: a key to Crohn's disease

Crohn's disease causes the immune system to produce too much of the TNF-alpha (tumor necrosis factor-alpha) protein.1 This can lead to painful, inconvenient symptoms and damage to the gastrointestinal (GI) tract.2

To learn more about the link between TNF-alpha and Crohn's disease, watch this video.

CIMZIA targets TNF-alpha

CIMZIA is a biologic medicine called a PEGylated anti-TNF. CIMZIA targets TNF-alpha and blocks it from causing inflammation in the GI tract. CIMZIA is the only PEGylated anti-TNF.1

References:

  1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
  2. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterol. 2000;119:1148-1157.
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA